ArticleJournal of endocrinological investigation2026
Plasma proteomics reveals potential biomarkers for the preoperative diagnosis of parathyroid carcinoma.
Article in Journal of endocrinological investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundParathyroid carcinoma (PC) is a rare endocrine malignancy with a poor prognosis. The preoperative diagnosis of PC is difficult because of the lack of specific clinical features and effective diagnostic methods. Proteomics research can provide new strategies for preoperative diagnosis, but the proteomic profile of plasma from PC patients is still unavailable. MEASURES: Plasma samples from 10 PC patients and 10 PA patients were collected before surgery, and quantitative label-free proteomics analysis was applied to explore the proteomic landscape of parathyroid neoplasms. Next, parallel reaction monitoring (PRM) analysis was used to verify the possible biomarkers in plasma from 24 PC patients and 46 PA patients. Finally, the expression of potential biomarkers in parathyroid tumor tissues was validated.
resultsCompared with those in PA patients, 76 overexpressed proteins and 62 underexpressed proteins were identified in the plasma of PC patients. These differentially expressed proteins were closely associated with the immune system according to functional enrichment analysis. PRM analysis revealed that four proteins, including myoglobin (p = 0.048), polymeric immunoglobulin receptor (pIgR) (p = 0.021), coronin-1 A (p = 0.024), and immunoglobulin heavy variables 2–26 (p = 0.029), were promising diagnostic biomarkers for PCs. Coronin-1 A (p = 0.038) and glucose-6-phosphate isomerase (p = 0.041) were significantly related to overall survival (OS) of PC patients. Moreover, coronin-1 A was confirmed to be significantly overexpressed in parathyroid carcinoma tissues.
conclusionThe proteomic profile of plasma from patients with PCs significantly differed from that of plasma from patients with PAs. Myolobin, pIgR, coronin-1 A and immunoglobulin heavy variable 2–26 in plasma may be potential biomarkers for the preoperative diagnosis of PCs. Coronin-1 A may serve as a novel biomarker for the differential diagnosis of parathyroid carcinoma in not only preoperative but also postoperative diagnosis.
Indexed as
Identifiers
41060520What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.